Express
Leading Biopharmaceutical Company Plans to Acquire Conflux to Expand into Blockchain Technology Sector
Summary: According to reports, listed company Leading Biopharmaceutical Company Limited (00399) announced the signing of a memorandum of understanding to acquire the target company's entire equity, contingent on the target company completing the acquisition of Conflux blockchain-related assets. The acquisition price will be paid in cash, company shares, or convertible bonds, with the specific amount to ...
According to reports, listed company Leading Biopharmaceutical Company Limited (00399) announced the signing of a memorandum of understanding to acquire the target company's entire equity, contingent on the target company completing the acquisition of Conflux blockchain-related assets. The acquisition price will be paid in cash, company shares, or convertible bonds, with the specific amount to be determined in the formal agreement. The memorandum of understanding is valid for 12 months, during which the seller may not negotiate or trade the target company's equity with other parties. Leading Biopharmaceutical Company hopes to expand its business into the blockchain technology sector through this acquisition, diversifying its business and seeking new sources of profit growth. However, the transaction still needs to be finalized after signing a formal agreement, and relevant announcements will be made in accordance with listing rules in due course. Shareholders and investors are advised to proceed with caution. It is reported that the Hong Kong stock market is closed today in observance of the establishment of the Hong Kong Special Administrative Region.
Tags:
Link: Leading Biopharmaceutical Company Plans to Acquire Conflux to Expand into Blockchain Technology Sector [Copy]